Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial

Harpreet S. Bajaj, Itamar Raz, Ofri Mosenzon, Sabina A. Murphy, Aliza Rozenberg, Ilan Yanuv, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Marc S. Sabatine, Stephen D. Wiviott, Avivit Cahn